THE CONSORTIUM-TO-ESTABLISH-A-REGISTRY-FOR-ALZHEIMERS-DISEASE (CERAD) .5. A NORMATIVE STUDY OF THE NEUROPSYCHOLOGICAL BATTERY
THE CONSORTIUM-TO-ESTABLISH-A-REGISTRY-FOR-ALZHEIMERS-DISEASE (CERAD) .5. A NORMATIVE STUDY OF THE NEUROPSYCHOLOGICAL BATTERY
复制标题
DOI：
10.1212/wnl.44.4.609
复制
发表时间：
1994-04-01
期刊：
影响因子：
9.9
通讯作者：
HEYMAN, A
中科院分区：
文献类型：
--
作者：
WELSH, KA;BUTTERS, N;HEYMAN, A
为该联盟建立阿尔茨海默病登记处(CERAD)而开发的神经心理测试目前被用于在阿尔茨海默病(AD)的临床调查中衡量该疾病的认知障碍。这份报告介绍了CERAD电池的规范信息，从1987年至1992年参加CERAD研究的美国23所大学医学中心登记的对照受试者(50岁至89岁)的大样本(n=413)中获得。我们分别比较了高分(112分)和低分(
The neuropsychological tests developed for the Consortium to Establish a Registry for Alzheimer's Disease (CERAD) are currently used to measure cognitive impairments of Alzheimer's disease (AD) in clinical investigations of this disorder. This report presents the normative information for the CERAD battery, obtained in a large sample (n = 413) of control subjects (ages 50 to 89) who were enrolled in 23 university medical centers in the United States participating in the CERAD study from 1987 to 1992. We compared separately the performance of subjects with high (112) and low (